Considerations for Schizophrenia Research in Adolescents

Schizophrenia Research in Adolescents
By Bartosz Janikowski, Vice President, Medical & Scientific Affairs,

The recent (January 2017) US Food and Drug Administration (FDA) approval of a supplemental new drug application for lurasidone (Latuda, Sunovion Pharmaceuticals Inc.) for the treatment of schizophrenia in adolescents aged 13 to 17 years, adds to the existing list of approved medications for the use in that subpopulation. Yet, it reminds us that there is still an unmet medical need for identification of new medicines given their currently observed response rates, safety profiles and cost, and also indirectly illustrates difficulties in conducting studies in children and adolescents with schizophrenia.

Read More

Treatment-Resistant Schizophrenia – New Definitions for Research and Clinical Use

By Bartosz Janikowski, M.D., Vice President, Medical & Scientific Affairs, Worldwide Clinical Trials,

Treatment-resistant schizophrenia is a phenomenon that most clinicians and researchers try to combat in their daily practices. Treatment-resistant schizophrenics are patients who are repeatedly admitted to hospitals or require frequent visits to specialists or, as study subjects, are often excluded from participation in efficacy and safety studies of new antipsychotic medications. That said, the research community faced various definitions of treatment-resistance and response to schizophrenia treatments and was also often not looking specifically into the issue of the adequate adherence to treatments provided sometimes resulting in confusion between treatment resistance and potential resistance to treatment.

Read More